Clinical Trial Detail

NCT ID NCT03130439
Title Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Abemaciclib

Age Groups: adult senior

Additional content available in CKB BOOST